JP2024538694A - シクロペンチルピラゾールcdk2阻害剤 - Google Patents

シクロペンチルピラゾールcdk2阻害剤 Download PDF

Info

Publication number
JP2024538694A
JP2024538694A JP2024520826A JP2024520826A JP2024538694A JP 2024538694 A JP2024538694 A JP 2024538694A JP 2024520826 A JP2024520826 A JP 2024520826A JP 2024520826 A JP2024520826 A JP 2024520826A JP 2024538694 A JP2024538694 A JP 2024538694A
Authority
JP
Japan
Prior art keywords
compound
pharma
ring
acceptable salt
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520826A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024538694A5 (cg-RX-API-DMAC7.html
Inventor
ジェシカ マリー グランドナー,
ケヴィン エム. ジョンソン,
スティーヴン マグヌスン,
ジェレミー マーク マリー,
ブレンダン ティー. パー,
ヴィシャル エー. ヴァーマ,
ヨン ワン,
ミンシュオ ツォン,
メリッサ エー. アシュレイ,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2024538694A publication Critical patent/JP2024538694A/ja
Publication of JP2024538694A5 publication Critical patent/JP2024538694A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2024520826A 2021-10-05 2022-10-04 シクロペンチルピラゾールcdk2阻害剤 Pending JP2024538694A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163252394P 2021-10-05 2021-10-05
US63/252,394 2021-10-05
PCT/US2022/077501 WO2023060057A1 (en) 2021-10-05 2022-10-04 Cyclopentylpyrazole cdk2 inhibitors

Publications (2)

Publication Number Publication Date
JP2024538694A true JP2024538694A (ja) 2024-10-23
JP2024538694A5 JP2024538694A5 (cg-RX-API-DMAC7.html) 2025-10-10

Family

ID=84245758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520826A Pending JP2024538694A (ja) 2021-10-05 2022-10-04 シクロペンチルピラゾールcdk2阻害剤

Country Status (10)

Country Link
US (1) US20240425478A1 (cg-RX-API-DMAC7.html)
EP (1) EP4412995A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024538694A (cg-RX-API-DMAC7.html)
KR (1) KR20240077491A (cg-RX-API-DMAC7.html)
CN (1) CN118019734A (cg-RX-API-DMAC7.html)
AR (1) AR127247A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022360968A1 (cg-RX-API-DMAC7.html)
CA (1) CA3229067A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330501A (cg-RX-API-DMAC7.html)
WO (1) WO2023060057A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3217792A1 (en) 2021-05-07 2022-11-10 Kymera Therapeutics, Inc Cdk2 degraders and uses thereof
WO2023092088A1 (en) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same
CA3250419A1 (en) * 2022-04-28 2025-07-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. CYCLOPENTANOL ESTER DERIVATIVE SUBSTITUTED BY PYRAZOLE AND ITS USE
WO2024104455A1 (zh) * 2022-11-17 2024-05-23 山东绿叶制药有限公司 Cdk2抑制剂及其制备方法和应用
WO2025136671A1 (en) * 2023-12-20 2025-06-26 Ensem Therapeutics, Inc. Anilino-pyrazole derivatives, compositions and methods thereof
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3128155C (en) * 2019-01-31 2023-09-19 Pfizer Inc. 3-carbonylamino-5-cyclopentyl-1h-pyrazole compounds having inhibitory activity on cdk2
CN113766125B (zh) 2019-09-29 2022-10-25 Oppo广东移动通信有限公司 对焦方法和装置、电子设备、计算机可读存储介质
MX2023009086A (es) * 2021-02-12 2023-08-08 Relay Therapeutics Inc Inhibidores de cinasas dependientes de ciclinas (cdk) y metodos de uso de estos.

Also Published As

Publication number Publication date
KR20240077491A (ko) 2024-05-31
AU2022360968A1 (en) 2024-02-29
EP4412995A1 (en) 2024-08-14
AR127247A1 (es) 2024-01-03
WO2023060057A1 (en) 2023-04-13
CN118019734A (zh) 2024-05-10
CA3229067A1 (en) 2023-04-13
US20240425478A1 (en) 2024-12-26
TW202330501A (zh) 2023-08-01

Similar Documents

Publication Publication Date Title
KR20240077491A (ko) 시클로펜틸피라졸 cdk2 억제제
EP4713330A1 (en) Tricyclic compounds and uses thereof
EP3112364B1 (en) 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom
KR102589213B1 (ko) 피리미딘 사이클로헥세닐 글루코코르티코이드 수용체 조절제
KR20130129244A (ko) 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
KR20140020823A (ko) Nampt의 억제를 위한 구아니딘 화합물 및 조성물
EP4034535B1 (en) Aza-quinoline compounds and uses thereof
JP2019518059A (ja) PI3Kβ阻害剤としてのアザベンゾイミダゾール誘導体
JP6545262B2 (ja) Ripk2阻害剤およびそれを用いた癌の治療方法
JP2023145547A (ja) Cd73阻害剤、その製造方法と応用
JP2020520960A (ja) アザアリール誘導体、その製造方法および薬学上の応用
EP4186905A1 (en) Compound serving as btk inhibitor, preparation method therefor, and use thereof
WO2023143147A1 (zh) 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
CA3145864A1 (en) Tyrosine kinase non-receptor 1 (tnk1) inhibitors and uses thereof
JP2019524678A (ja) ヘッジホッグ経路アンタゴニスト活性を持つキラル複素環式化合物、及びその製造方法、並びに応用
EP3705480A1 (en) Class of amino-substituted nitrogen-containing fused ring compounds, preparation method therefor, and use thereof
EP4293029A1 (en) Azaheteroaryl compound, preparation method therefor, and application thereof
IL301275A (en) Heterocyclic heteroaryl compounds and their uses
JP7053654B2 (ja) PI3Kβ阻害剤としてのキノキサリン及びピリドピラジン誘導体
CN118139846A (zh) 一种egfr小分子抑制剂、含其的药物组合物及其用途
CN115215862A (zh) 嘧啶酮化合物及其用途
CN117659049A (zh) 取代桥环类抑制剂及其制备方法和应用
JP2019518032A (ja) Pi3k beta阻害薬としての二環式ピリジン、ピラジンおよびピリミジン誘導体
JP2024500919A (ja) 重水素化コロニー刺激因子-1受容体(csf-1r)阻害剤
EP4168413B1 (en) N-linked macrocyclic 4-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251002